Breast Carcinoma-Associated Antigen, Serum

Casandra

Casandra Test Code MC82685Version 1 (DRAFT)

Performing Lab

Lab Mayo Clinic LabLab Test ID C2729CPT Code 86300

Breast Carcinoma-Associated Antigen, Serum

Clinical Use

Use

Aiding in the management of breast cancer in patients with metastatic disease by monitoring the progression or regression of disease in response to treatment. Useful for serial testing in women with prior stage II or III breast cancer who are clinically free of disease. May predict early recurrence of disease in women with treated carcinoma of the breast. Not useful for screening women for or diagnosis of carcinoma of the breast.

Special Instructions

CA 27.29 is cleared or approved by the US FDA for use, and testing should be part of a broader diagnostic strategy in combination with other methods. Heterophilic antibodies or exposure to mouse antigens may interfere with results. Exercise caution when interpreting concentrations during pregnancy. Specimens should be centrifuged and aliquoted within 2 hours of collection or the test will be canceled, and they should then be sent refrigerated.

Limitations

Measurement of CA 27.29 is not useful for screening or diagnosis but for monitoring. Normal concentrations do not always rule out disease presence and elevated levels can be observed in nonmalignant conditions. Test has limitations related to heterophilic antibodies interference and requires use with other diagnostic evaluations. Differences in assay methods or kits may lead to variations in results which should not be used interchangeably.

Test Details

FDA Approved